عرض بسيط للتسجيلة

المؤلفGupta, Ishita
المؤلفHussein, Ola
المؤلفSastry, Konduru Seetharama
المؤلفBougarn, Salim
المؤلفGopinath, Neha
المؤلفChin-Smith, Evonne
المؤلفSinha, Yashi
المؤلفKorashy, Hesham Mohamed
المؤلفMaccalli, Cristina
تاريخ الإتاحة2023-11-12T08:29:24Z
تاريخ النشر2023-10-01
اسم المنشورAdvances in Cancer Biology - Metastasis
المعرّفhttp://dx.doi.org/10.1016/j.adcanc.2023.100107
معرّف المصادر الموحدhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85166953610&origin=inward
معرّف المصادر الموحدhttp://hdl.handle.net/10576/49188
الملخصCancer immune evasion is one of the principal mechanisms leading to the progression and metastatization of the disease. Despite the migration and infiltration at the tumor site of immune cells, multiple factors can influence the composition of hot or “immune-sensitive” tumors and cold or “immune-resistant” tumors. Among the multiple mechanisms responsible for the make-up of the tumor microenvironment are the expression levels of major histocompatibility molecules (MHC) and of the antigen processing machinery, the metabolic network, hypoxia, and the secretion of pro-inflammatory molecules (e.g., cytokines, chemokines, and growth factors). Moreover, the different triggered pathways can mediate the reprogramming of activated, memory, effector, or regulatory/tolerogenic subtypes of immune cells (T, NK, dendritic cells, and macrophages). Recent studies have focused on the role of cancer metabolism in evading immune surveillance through the action of the active tryptophan catabolic enzyme indoleamine 2,3-dioxygenase (IDO). Immune suppression and evasion mechanisms in cancer cells are now being extensively studied with a special focus on developing immunotherapy strategies, such as the targeting of immune checkpoints (programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1), Cytotoxic T-lymphocyte antigen-4 (CTLA-4)), adoptive cell therapy or cancer vaccines. In this review, an overview of the underlying mechanisms of cancer immune evasion and the efficacy of the therapeutic targets and agents to overcome the immune escape are described.
راعي المشروعThis has been supported by the QNRF grants: NPRP10-0129-170277) and GSRA8-L-1-0506-21033.
اللغةen
الناشرElsevier
الموضوعCancer stem cells
Circulating tumor cells
Epithelial-mesenchymal transition
Immune evasion
Immunotherapy
Micro-RNAs
العنوانDeciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications
النوعArticle Review
رقم المجلد8
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة